 Cancers located in the upper aerodigestive tract of the head and neck region present unique management challenges due to the anatomic density of the region. These include as for all cancers effective management of all clinically evident cancer cells and sub-clinical cancer cells based on a knowledge of their anatomic location 2. For head and neck cancers, the anatomic density of this region of the body presents a significant risk for cancer therapies injuring important upper aerodigestive functions. In particular, swallowing function and its dysfunction ie. dysphagia can have multi-faceted consequences for the head and neck cancer patient including serious quality of life impairments 3 and the potential risk of late mortality with evidence to date suggest that aspiration lung injury may be a major cause 1, 4. In fact, functional considerations have had a profound influence on the history of head and neck cancer therapy development. 